Upper tract urothelial carcinoma (UTUC) accounts for 5% of urothelial carcinomas (UCs), the estimated annual incidence being 1-2 cases per 100,000 inhabitants. Similarly to bladder UC, divergent differentiations and histologic variants confer an adverse risk factor in comparison with pure UTUC. Molecular and genomic characterization studies on UTUC have shown changes occurring at differing frequencies from bladder cancer, with unique molecular and clinical subtypes, potentially with different responses to treatment. Systemic chemotherapy is the standard approach for patients with inoperable locally advanced or metastatic UCs. Although initial response rates are high, the median survival with combination chemotherapy is about 15 months. In first-line chemotherapy several cisplatin-based regimens have been proposed. For patients with advanced UC who progress to first-line treatment, the only product licensed in Europe is vinflunine, a third-generation, semisynthetic, vinca alkaloid. Better response rates (15-60%), with higher toxicity rates and no overall survival (OS) benefit, are generally achieved in multidrug combinations, which often include taxanes and gemcitabine. The US FDA has recently approved five agents targeting the programmed death-1 and programmed death ligand-1 pathway as a secondline therapy in patients with locally advanced or metastatic UC with disease progression during or following platinum-containing chemotherapy. Potential therapeutic targets are present in 69% of tumours analyzed. Specific molecular alterations include those involved in the RTK/Ras/PI(3)K, cell-cycle regulation and chromatin-remodeling pathways, many of them have either targeted therapies approved or under investigation. Angiogenic agents, antiepidermal growth factor receptor therapy, phosphoinositide 3-kinase (PI3K) and mammalian target of rapamycin (mTOR) pathway inhibitors and immunotherapeutic drugs are being successfully investigated.
Introduction
Upper tract urothelial carcinoma (UTUC) accounts for 5% of urothelial carcinomas (UCs), the estimated annual incidence being 1-2 cases per 100,000 inhabitants. 1 The pathology of UTUC has been considered to be the same as that of bladder UC (BUC). Such an assumption appears to be reasonable due to the fact that the morphologic features of UTUC and BUC are identical microscopically. However, a growing body of evidence has accumulated suggesting that there are differences between these two neoplasms and that UTUC and BUC are two disparate entities. 2 The vast majority of neoplasms of the upper urinary tract are UCs. Even though pure squamous cell carcinoma, adenocarcinoma, and neuroendocrine carcinoma, among others, do occur, more commonly seen are areas of squamous differentiation and, less frequently, glandular differentiation within an otherwise usual UC. 3 Pure UCs can display a host of variant histologies. Recognition of such morphologies is of paramount important for proper diagnosis, prognosis and therapy. Histological variants are associated with advanced tumour stage, tumour multifocality, sessile tumour architecture, tumour necrosis, lymphovascular invasion and lymph node metastasis, in comparison with pure UTUC. Outcomes associated with variant histology are worse than with pure UC on univariable analysis. In particular, it is associated with disease recurrence and cancer-specific mortality. However, such an effect does not retain significance on multivariable evaluation. 4 In patients treated with adjuvant chemotherapy there are no differences in disease recurrence or survival between variant histology and pure UTUC. 5 Other variants have been described in the bladder but have not yet been fully described in the UTUC, such as the lipid-rich (lipoid) variant, UC with small tubules, and the large nested variant of UC, among others. Any tumour that may be seen in the bladder may also, theoretically, occur in the ureter and pelvis. These should be considered in the differential diagnosis when examining tumours of such locations. 6 
Tumour grade
The 1973 World Health Organization (WHO) classification was the international standard for UC grading. It distinguishes grades G1-G3. 7 The 2004 WHO classification 8 (currently also known as the 2016 WHO classification) distinguishes in the noninvasive papillary tumours, papillary urothelial neoplasia of low malignant potential, and low-and high-grade carcinoma (low grade versus high grade for the invasive forms). The current guidelines are based on the 2016 WHO classifications. 9 Tumour node metastasis staging The 8th AJCC and UICC edition of the tumour, node, metastasis (TNM) classification is identical to the previous 7th edition. 10 Concerning the correlation between biopsy tumour stage and resection tumour stage, staging upper urinary tract tumours is fraught with difficulties, mainly due to the small size of the biopsy material submitted for diagnosis. The muscularis propria is rarely seen in the biopsies of the upper tract. Some biopsies may be so small and superficial that only the epithelium is present, thus precluding assessment of invasion entirely. A study by Vashistha and colleagues reported a pT stage concordance of 60% for biopsies. A pT classification was not feasible in 10.6% of cases. 11 Patients with an advanced clinical stage (cT3-4) or with clinically enlarged lymph nodes (cN+) are potential candidates for neoadjuvant chemotherapy (NAC), even though the influence of NAC on OS showed no statistically significant benefit. 12 Lymph node dissection performed at the time of renal nephroureterectomy (RNU) allows for optimal tumour staging. Its curative role is debated. The regional lymph nodes are the hilar and retroperitoneal nodes, and for the mid and distal ureter, the intrapelvine nodes. The only difference between the 7th and the 8th editions is that, since there are no data to substantiate the three N categories in the 7th edition, the previous category of N3 metastasis in a lymph node greater than 5 cm is now collapsed with N2 in the 8th edition. Lymph node metastases and extranodal extension are predictors of survival outcomes in UTUC. 13 Lymphovascular invasion (LVI) is seen in about 20% of the UTUCs. Since it is an independent predictor of survival, LVI should be specifically included in the pathology reports of all UTUC specimens. 14 Positive soft tissue surgical margin (R) after RNU is a factor for disease recurrence. Uropathologists should look for surgical margins and report positive margins at the level of ureteral transection, bladder cuff, and around the tumour if the T stage >2. 15 Since tumour stage is difficult to assess clinically in UTUC, it is useful to 'risk stratify' UTUC into journals.sagepub.com/home/tau 3 low-and high-risk neoplasms to identify those patients who are more suitable for renal sparing treatment versus radical extirpative surgery 16 ( Figure 1 ).
Additional pathological features
The architecture is a strong prognosticator with sessile growth pattern being associated with worse outcome. Concomitant CIS in organ-confined UTUC and a history of bladder CIS are associated with a higher risk for recurrence and cancerspecific mortality. 17 Tumour necrosis (i.e. >10% of the tumour area) is present in approximately 20% of the patients. Its prevalence increases with advancing pathological stage, from 7% and 10.6% to 50% in T1, T2 and T3-4, respectively. In addition, tumour necrosis is associated with features of aggressiveness in UTUC, including a high grade, lymph node metastasis, LVI, a sessile architecture of the tumour and concomitant CIS. Tumour necrosis is not an independent predictor of clinical outcomes. 18 Predictive tools Several predictive tools have been proposed in UTUC, both in the preoperative and postoperative settings. At present, the Yates' model remains the only one to have been validated in a different population. 19 As the current staging system is not useful in the neoplasms of the UTUC prior to RNU, new prognostic factors and tools are needed in the decision-making process. This will help clinicians in the identification of high-risk patients who will benefit from certain types of therapy and those who could be spared from the side effects of an unnecessary therapeutic intervention. In order to select such patients, highly accurate tools estimating individual prognosis are needed. As for the variants, as recently stated by Moschini and colleagues for the urinary bladder, their clinical relevance can manifest at three different levels: 'diagnostic, as identification is challenging and misinterpretation is not uncommon; prognostic, for patient risk stratification and outcome estimation; and therapeutic, as particular variants could be responsive to specific treatment strategies'. 20 The same applies to UTUC and its variants.
Molecular and genetic markers
Several studies have investigated the prognostic impact of markers related to cell adhesion, cell differentiation, angiogenesis, cell proliferation (Ki-67), epithelial-mesenchymal transition, mitosis, apoptosis, and vascular invasion, and c-met protein. 21 Microsatellite instability (MSI) can help detect germline mutations and hereditary cancers. It is an independent molecular prognostic marker. 22 Several molecular markers have been associated with worse outcomes of UTUC. Because of the rarity of UTUC, the main limitations of such studies are their retrospective design and small sample size. None of the markers have fulfilled the criteria necessary to support their introduction in daily clinical decision making. Ki-67 is the only one that has been prospectively evaluated. 23 Targeted next-generation sequencing of 300 cancer-associated genes has been performed in order to define the genomic landscape of UTUC and to compare its results with BUC. The spectrum of genes mutated in UTUC and BUC is similar. However, differences in the prevalence of alterations in several recurrently mutated genes, including FGFR3, HRAS, TP53, and RB1 were seen. 24, 25 Such data can provide an important reference for the development of multimodal strategies in the management of UTUC. The high prevalence of potentially actionable genetic events in UTUC suggests that routine genomic profiling may speed up the process of developing novel drug targets. In particular, the 'association of MVAC is the first combination regimen which demonstrated, based on the results of randomized clinical trials, a clear superiority compared with single-agent cisplatin. [32] [33] [34] MVAC showed a significant improvement in the overall response rate (OR; 39% versus 12%) and progression-free survival (PFS; 10 versus 4 months; OS, 13 versus 8 months). Toxicity is a major concern with the MVAC regimen, particularly since many patients with advanced UC are elderly or have multiple comorbidities and in the case of UTUCs patients often show impaired renal function after radical surgery. [32] [33] [34] Myelosuppression, neutropenic fever, sepsis, mucositis, and nausea and vomiting are common. The use of hematopoietic growth factor support may reduce the rate, grade and length of some of these toxicities, especially myelosuppression and mucositis. 33 In a phase III randomized trial, MVAC was compared with the combination of GC. In terms of OR (49 versus 36%) and 5-year survival (PFS of both arms, 7 months, OS 14 versus 15 months) the two regimens appeared equivalent. However, toxicity was significantly less in the GC arm with less serious (grade 3/4) neutropenia (71 versus journals.sagepub.com/home/tau 5 82%), neutropenic sepsis (2 versus 14%), and mucositis (1 versus 22%). 31 This trial was designed to assess whether GC was superior and was not powered to demonstrate equivalency between the two regimens, but given the similar efficacy and lesser toxicity, GC is widely considered the standard first-line regimen for patients with advanced BUC and upper urinary tract.
In an effort to improve outcomes and lower toxicity with MVAC therapy, the European Organisation for Research and Treatment of Cancer (EORTC) investigated the potential role of high-dose MVAC (hd-MVAC), which consisted of rapid 2-week cycles (instead of the standard 4 weeks). A total of 246 patients were randomized to receive either standard MVAC or hd-MVAC. Although the OR and OS rates were similar, PFS was significantly improved (9.5 months versus 8.1 months, p = 0.037) and toxicity was decreased in patients treated with hd-MVAC. 35 In order to improve the outcome obtained with the dual therapy, attempts were made to incorporate a third agent to the doublet of GC. The triplet combination of paclitaxel, gemcitabine, plus cisplatin (PGC) was demonstrated in the EORTC 30987 phase III study, which enrolled 626 patients with advanced UC (81% with primary bladder cancer) and randomly assigned them to treatment with GC or PGC for a maximum of six cycles. Final results after a median follow up of 4.6 years have been reported. 36 Currently, the only product licensed for secondline chemotherapy in Europe is vinflunine, a third-generation, semisynthetic, vinca alkaloid. A phase III study comparing vinflunine with best supportive care showed a significant survival benefit in eligible patients (6.9 versus 4.3 months), with an objective response rate (ORR) of 8.6%. 48 The choice of second-line chemotherapy is complex and depends on performance status, first-line treatment used, prior chemosensitivity in terms of duration of response, and the presence of visceral metastases. The most important predictors of poor outcome in the second-line setting are hemoglobin level, presence of liver metastasis, poor performance status and time from prior chemotherapy. 49, 50 For selected patients who progress on first-line cisplatin-based chemotherapy and are still eligible for cisplatin treatment, rechallenge with cisplatin-containing chemotherapy is feasible, depending on their initial response. 51, 52 Several other single-agent chemotherapies including paclitaxel, docetaxel, gemcitabine, ifosfamide, oxaliplatin, pemetrexed and nab-paclitaxel [53] [54] [55] [56] [57] have been tested in second-line therapies with response rates ranging from 5% to 33%, short times to progression and no improvement in OS. Better response rates (15-60%), with higher toxicity rates and no OS benefit, are generally achieved in multidrug combinations, which often include taxanes and gemcitabine. [58] [59] [60] [61] 
Target therapies
In recent years, also in UC, a better and wider knowledge of the cancer genome has revealed both well-characterized and novel genomic alterations, with extensive work performed in more advanced disease, leading to studies on target therapies. 62, 63 Potential therapeutic targets were present in 69% of tumours analyzed. Specific molecular alterations included those involved in the RTK/Ras/PI(3)K, cell-cycle regulation and chromatin-remodeling pathways, many of which have either targeted therapies approved or under investigation. 64 Gene expression profiling by several groups has suggested there are intrinsic subtypes of BUC that may differ in their underlying biology and overall prognosis, potentially having advantage from different therapeutic approaches. 65, 66 This likely reflects a difference in the underlying biology of UTUC, since luminal subtype 66 and fibroblast growth factor receptor (FGFR) mutations 25 have been reported to occur with higher frequency in these patients. 68 While no alterations in Rb1 were found in 59 high-grade UTUC tumours in the primary study, the smaller study found three Rb1 alterations in 19 samples, supporting the need for independent validation.
Over the last decade, multiple molecular alterations in this pathway have been implicated in many different cancers. A recent analysis of driver cancer genes across various tumour types identified significant alterations in PI3K-AKT-mTORsignaling components especially PIK3CA in bladder, endometrial, breast, lung and head and neck cancers. 69 Recent genomic analyses of two large cohorts of UC patients showed frequent alterations in PIK3-AKT-mTOR pathway. The largest analysis from the TCGA network, which included a cohort of 131 chemotherapy-naïve high-grade muscle-invasive UC patients (T2-T4a, Nx, Mx), reported mutations and copy number alterations within this pathway in 42% of tumours. 70 
Antiangiogenic agents
Angiogenic agents have been tested in UC in different clinical studies, with discordant results.
Bevacizumab, a monoclonal antibody directed against the vascular endothelial growth factor (VEGF), showed promising results. In a phase II trial in which bevacizumab was combined with GC as a first-line treatment of metastatic UC, a journals.sagepub.com/home/tau 7 72% OR and a median OS of 19.1 months, was reported. 71 In another phase II study chemonaïve patients with metastatic disease, whose expected survival was approximately 9 months, bevacizumab combined with gemcitabine and carboplatin led to a 63% response rate and OS of 13.9 months. 72 In both trials an advantage against historical controls was observed. In the neoadjuvant setting, in a phase II trial, bevacizumab was combined with MVAC, resulting in an increased pathologic response, to less than stage T2. 73 More disappointing were results with tyrosine kinase inhibitors that target VEGF receptors (VEGFRs). Sunitinib, a multikinase inhibitor, that targets VEGFRs and also c-kit, plateletderived growth factor receptor (PDGFR)-a and -b, Fms-related tyrosine kinase 3 and RET, was studied as second-line therapy using two different schedules. A partial response was seen in 5% of patients, with OS reported as 6.9 months. The treatment was not well tolerated, 74% of the patients experienced grade 3 and 4 toxicities, most common adverse events were lymphopenia, thrombocytopenia, anemia, fatigue and nausea. 74 In another study, sunitinib was given as first-line treatment in patents ineligible for cisplatin, due to renal impairment. An 8% response rate and 8.1-month OS were reported. Although the incidence of grade 3 and 4 toxicities was less, 2 of 38 patients died (1 of myocardial infarction and 1 of stroke), possibly related to treatment. 75 Finally, sunitinib given as maintenance therapy in a phase II trial to patients who had achieved stable disease, partial or complete response after 4-6 cycles of chemotherapy did not improve 6-month PFS compared with placebo. 76 Because of these disappointing results, no trials of sunitinib for metastatic UC are ongoing.
Other antiangiogenic agents have been investigated for efficacy against UC.
Sorafenib, which targets VEGFR-2 and -3 and B-Raf, c-Raf, and PDGFR-a and -b, achieved no response as either first-line treatment for cisplatin-ineligible patients or single-agent secondline treatment. 77, 78 These studies led researchers to conclude that sorafenib has little or no activity against UC. Similarly, in a trial of pazopanib, an antiangiogenic agent that targets VEGFR-1, -2, and -3, PDGFR-a and -b, and c-kit, the drug effected no response when given as a single agent in second-line treatment 79 and led to a 17% response rate in another trial, with a median OS of only 4.7 months. 80 A trial of pazopanib combined with GC as first-line treatment for cisplatin-ineligible patients (NCT01622660) closed because of hepatotoxicity. A trial of pazopanib combined with vinflunine as second-line treatment was discontinued at the first dose level for safety reasons. 81 Although small molecule inhibitors of VEGFR have so far shown limited efficacy, a three-arm randomized phase II study of recently developed monoclonal antibodies targeting VEGFR-1 (icrucumab) and VEGFR-2 (ramucirumab) combined with docetaxel in patients with disease progression after first-line therapy has been recently published. It showed how a combination of docetaxel and ramucirumab improved PFS than docetaxel alone (5.4 versus 2.8 months); icrucumab instead did not experience any PFS improvement. 82 
Anti-epidermal growth factor receptor therapy
Progression of muscle-invasive UC has been linked to epidermal growth factor receptor (EGFR) overexpression. 83, 84 When 20 patients with muscle-invasive disease were treated with erlotinib before cystectomy, 60% were downstaged to pT1 or less, suggesting single-agent activity with EGFR inhibitors. 85 However, gefitinib administered as a single agent in secondline treatment produced only a 3% response rate and a 3-month OS. 86 Moreover, gefitinib combined with GC, given either as a standard dose 87 or at a fixed-dose rate, 88 did not improve either the response rate or OS for patients with untreated metastatic UC.
Furthermore, the combination of GC chemotherapy and cetuximab, a monoclonal antibody targeting EGFR, was intolerable, and both PFS and median OS proved detrimental. 89 A randomized phase II trial of another EGFR-specific monoclonal antibody, panitumumab, combined with GC compared with chemotherapy alone as first-line treatment was terminated early because of insufficient recruitment (NCT01374789).
Another randomized phase II trial of patients with previously treated metastatic disease reported a 25% response rate for cetuximab combined with paclitaxel, but no activity for cetuximab as a single agent. 90 These data support preclinical data showing synergism between anti-EGFR monoclonal antibodies and taxanes. 91 Overall, it appears that in unselected patients, targeting EGFR has limited efficacy. Therefore, it is imperative to identify biologic markers, most likely to identify patients responding to anti-EGFR treatment. The oral tyrosine kinase inhibitor vandetanib, was studied in the second-line setting combined with docetaxel in a phase II double-blind trial that reported no significantly improved OR, PFS, or OS in patients with advanced UC. 92 A single-arm phase II study tested the safety and efficacy of the antihuman EGFR-2 (HER2) antibody trastuzumab combined with GC, carboplatin, and paclitaxel in patients with HER2 overexpression found by immunohistochemistry, gene amplification, or elevated serum HER2 levels. 93 The patient outcomes exceeded expectations, with an ORR of 70% and an OS of 14.1 months. 93 Although the incidence of grade 1-3 cardiac toxicity (22.7%) was more frequent than anticipated, these unexpected results prompted additional studies. A randomized phase II trial compared trastuzumab (NCT01828736) with GC or GC and carboplatin versus GC or GC and carboplatin alone in HER2-expressing bladder cancer. 94 That study screened 563 patients with advanced UC over 5 years and found only 75 patients (13.3%) with HER2-positive (HER2+) tumours. No difference was observed in the ORR, PFS, or OS between the chemotherapyalone arm and the chemotherapy-plus-trastuzumab arm. The investigators did find that the HER2 levels were predictive of PFS regardless of treatment. A study investigating trastuzumab combined with standard GC chemotherapy in the first-line setting closed enrolment early (NCT02006667). Another study investigating trastuzumab as a single agent in the second-line setting (NCT02013765) closed early because of recruitment difficulties.
Lapatinib, an agent that has selective activity against both EGFR and HER2, was hypothesized to have significant clinical activity.
Although lapatinib had only a 1.7% response rate as a single agent in unselected patients with platinum-refractory metastatic UC, it led to a marked difference in OS in those with low EGFR/HER2 compared with patients with high EGFR or high HER2. 95 This subgroup analysis reinforces the concept of selecting appropriate patients for targeted therapies. In a recently completed trial that combined lapatinib with GC (GCL), four cycles of GCL were administered as neoadjuvant therapy for patients with muscle-invasive UC. Although initially designed as a phase II efficacy study with a primary endpoint of pathologic complete response at the time of radical cystectomy, the dose selected for investigation proved excessively toxic. 96 protein is an important target for therapeutic intervention. 100 However, the results of two phase II clinical trials of mTOR inhibitors as a single-agent therapy in UC patients have not been promising in unselected patients. 101, 102 In a phase II single-arm, nonrandomized study with everolimus in 45 UC patients who had progressed on cytotoxic agents, 1 patient had near complete response, 1 had a partial response, and several had minor responses. The primary end point of 2-month PFS in more than 70% of patients was not achieved. 101 Subsequent whole genome sequencing of the patient who showed near complete response to everolimus in the study had nonsynonymous mutations in the tuberous sclerosis complex, lending biomarker credibility to this regulator of mTOR. 103 Analysis of another phase II study of everolimus in platinum-resistant patients led to the conclusion that intact PTEN activity was required for mTOR inhibitor sensitivity due to feedback through AKT. 103, 104 Recently, a phase I study of an mTOR inhibitor in combination with pazopanib has been reported in which a patient who showed a 14 month complete response to therapy had two activating mutations in mTOR. 105 Another phase II study of the dual PI3K and mTOR inhibitor BEZ235 in patients with locally advanced or metastatic transitional cell carcinoma showed modest clinical activity and an unfavourable toxicity profile; however, a minority of patients experienced a clinical benefit, suggesting that a complete blockade of the PI3K/ mTOR axis could improve the outcome in some specific patients. 106 These findings highlight the importance of biomarker-enriched trial designs in UC-targeted therapy trials.
Immunotherapy
Resistance to cell death and evasion of immune destruction are known cancer hallmarks. 107 Progress in immunotherapy clinical trials across various tumour types promises to deliver significant benefit to patients with several solid tumour types including UC. 108 Newer immunotherapeutics are being investigated in multiple settings including ipilimumab, a monoclonal antibody against CTLA-4 (cytotoxic T lymphocyte antigen 4), which is already approved by the US FDA for the treatment of advanced melanoma. As a monotherapy in the neoadjuvant setting, a trial was performed to evaluate the safety of ipilimumab and immune monitoring in 12 patients with localized UC prior to cystectomy. Overall, two of six patients in the high-dose cohort had to delay surgery due to immune-related adverse events (AEs), though all patients recovered, and toxicity was generally limited to grades 1-2. Immune correlates were associated with OS in a companion study in patients with melanoma. 109 Another phase II study is evaluating the addition of immunotherapy to chemotherapy by using gemcitabine, cisplatin and ipilimumab as the first-line drugs in the treatment of UC is currently recruiting patients. In this study total of six cycles of chemotherapy are planned with ipilimumab to be added from the third cycle onwards. 110 Both programmed death-1 (PD-1) and programmed death ligand-1 (PD-L1) antibodies, are an exciting strategy to treat metastatic UC, including UTUC. Several checkpoint inhibitors are in later-stage clinical development as first-line and second-line therapies for metastatic UC.
A phase Ib trial evaluated pembrolizumab, a PD-1 inhibitor, in recurrent, metastatic, or persistent UC whose tumours on immunohistochemistry showed ⩾1% PD-L1-positive cells. 111 The ORR was 25%, and in patients with measurable disease, ORR was 38% in PD-L1-positive tumours. At 12 months, 19% continued to maintain a response. Pembrolizumab has been investigated also in chemo-naïve patients ineligible for a cisplatin phase II trial. Preliminary results recently presented showed an ORR of 24%. This trial was interestingly conducted in an elderly population with a median age of 75 years (range 44-94 years), but a 34% of patients older than 80 years. Further data are to be published. 112 A phase III study comparing pembrolizumab with either paclitaxel or docetaxel or vinflunine in patients with pretreated advanced UC has recently been published (Keynote 045). The end points were OS and PFS, which were assessed among all patients and among patients who had a tumour PD-L1 positivity. The median OS in the total population was higher in the pembrolizumab group, than in the chemotherapy group (10. were still receiving the drug at the data cut off. 116 Rosenberg and colleagues recently published outcomes from a phase II trial evaluating atezolizumab, a PD-L1 inhibitor. 117 The trial enrolled 316 patients who were either (1) chemotherapynaïve and cisplatin-ineligible or (2) cisplatinrefractory. The trial incorporated the evaluation of immune cell (IC) PD-L1 expression (grading IC0-IC3), TCGA cluster subtype, and mutation load. UTUC was the primary site for 21% of all patients and 16% of patients who were IC2/3. The ORR for IC2/3, IC1/2/3 and all patients was 26, 18, and 15%, respectively. The 12-month OS was 48% in the IC2/3 group and 36% in the intentionto-treat group compared with the historical rate of 20% in patients receiving second-line therapy. Median OS for IC2/3, IC1/2/3 and all patients was 11. Patients with a high interferon-γ signature were more likely to respond to nivolumab than were those with a low interferon-γ signature (p = 0·0003). The strongest interferon-γ signature was noted in patients with a basal 1 subtype. These patients were more likely to have a high interferon-γ signature score than patients with the other subtypes. 119 Results from this trial granted accelerated approval also for this drug in February 2017. Other trials with other target agents and immunotherapy are summarized in Tables 1 and 2 respectively. 
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